[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Ishii N, Yonese J, Tsukamoto T, Maezawa T, Fukui I, Ishikawa Y, Aoki N: [Multiple synchronous primary malignant tumors of fibrosarcoma and squamous cell carcinoma in the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2002 Jul;93(5):642-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple synchronous primary malignant tumors of fibrosarcoma and squamous cell carcinoma in the urinary bladder: a case report].
  • A 65-year-old housewife presented with a diagnosis of malignant spindle cell tumor of the bladder which had been diagnosed by work up for chance hematuria.
  • Computed tomography and magnetic resonance images showed a markedly enhanced mass, 4 cm in diameter, on the anterior wall of the urinary bladder, which appeared to be adhesive to the pubic bone.
  • Under the suspicion of sarcoma of the urinary bladder, we performed anterior pelvic exenteration with construction of an ileal conduit.
  • Although the anterior wall of the urinary bladder was mildly adhesive to the pubic bone, the surgical margin was negative for malignant cells.
  • The tumor corresponded to a fibrosarcoma that infiltrated the adipose tissue surrounding the urinary bladder.
  • The entire mucosa of the bladder showed diffuse squamous metaplasia, and well differentiated squamous cell carcinoma with pearl formation was found in part.
  • These two malignant tumors were clearly apart from each other, resulting in the histologic diagnosis of synchronous multiple malignant tumors of the bladder.
  • The patient developed a local relapse and pulmonary metastasis of fibrosarcoma one month postoperatively and died two month later without any response to chemotherapy (CYVADIC) and radiotherapy.
  • The current case seems to be the first one in Japan (third in the world) of a patient with multiple synchronous primary malignant tumors, carcinoma and sarcoma, airsing in the urinary bladder.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Fibrosarcoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174642.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


2. Hoshi S, Sasaki M, Muto A, Suzuki K, Kobayashi T, Tukigi M, Ono K, Sugano O, Saso S: Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy. Int J Urol; 2007 Jan;14(1):79-81
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy.
  • Carcinosarcoma of the bladder is an unusual malignancy characterized by an intimate admixture of malignant epithelial elements (carcinoma) and malignant soft tissue elements (sarcoma).
  • Cystectomy or transurethral resection is the preferred treatment, often followed by radiation therapy, although prognosis is very bad.
  • We herein report a case of carcinosarcoma of bladder obtained pathologically complete response by neoadjuvant chemoradiotherapy.
  • To our knowledge, it is the first case where urinary bladder carcinosarcoma obtained a pathologically complete response by chemoradiotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinosarcoma / drug therapy. Carcinosarcoma / radiotherapy. Deoxycytidine / analogs & derivatives. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Remission Induction

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17199866.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Number-of-references] 10
  •  go-up   go-down


3. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of bladder tumours in a single institution in Malaysia.
  • OBJECTIVE: To determine the clinicopathological features of bladder tumours encountered over a five year period in Universiti Kebangsaan Malaysia Medical Centre.
  • METHODS: Medical records of bladder tumour cases from 2005 till 2009 were retrospectively reviewed and tabulated.
  • The main histopathology was transitional cell carcinoma (TCC) (90.4%), followed by adenocarcinoma (6%), squamous cell carcinoma (1.2%), leiomyoma (1.2%) and myeloid sarcoma (1.2%).
  • All the adenocarcinomas and squamous cell carcinomas were treated by radiotherapy due to the advanced stage of the disease while the myeloid sarcoma received chemotherapy.
  • CONCLUSION: The incidence of bladder tumours is highest among the Chinese.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


Advertisement
4. Al-Quran SZ, Olivares A, Lin P, Stephens TW, Medeiros LJ, Abruzzo LV: Myeloid sarcoma of the urinary bladder and epididymis as a primary manifestation of acute myeloid leukemia with inv(16). Arch Pathol Lab Med; 2006 Jun;130(6):862-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma of the urinary bladder and epididymis as a primary manifestation of acute myeloid leukemia with inv(16).
  • Myeloid sarcoma (MS) of the lower urinary tract is rare.
  • We describe a 47-year-old man with hematuria, who was subsequently found to have MS involving bladder and epididymis.
  • Although blood and bone marrow examinations showed no morphologic evidence of leukemia, conventional cytogenetic studies of marrow demonstrated inv(16)(p13q22) in 4 of 20 metaphases; fluorescence in situ hybridization of the bladder neoplasm also showed inv(16).
  • Following chemotherapy, the patient has been in complete remission for 32 months.
  • In our literature review, we identified 7 cases of MS involving bladder, only 3 without evidence of an associated myeloid neoplasm in marrow, none with cytogenetic data.
  • A high index of suspicion is required to establish the diagnosis of MS involving bladder.
  • Cytogenetic analysis is useful for both demonstrating minimal marrow disease and classifying MS in paraffin-embedded tissue sections.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 16. Genital Neoplasms, Male / pathology. Sarcoma, Myeloid / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cytarabine / administration & dosage. Cytogenetic Analysis. Disease-Free Survival. Humans. Idarubicin / administration & dosage. In Situ Hybridization. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740041.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


5. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB: Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol; 2007 Jan-Feb;25(1):38-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of the M.D. Anderson experience in the treatment of bladder sarcoma.
  • OBJECTIVE: To assess the histologic subtypes, clinical presentations, treatment approaches, and treatment-related outcomes of patients with bladder sarcoma.
  • METHODS: Between January 1985 and July 2004, 19 patients (12 men and 7 women) with primary bladder sarcoma were evaluated at the University of Texas M.D.
  • The histologic subtypes of bladder sarcoma were leiomyosarcoma (N = 14), angiosarcoma (N = 3), and unclassified sarcoma (N = 2).
  • The clinical presentation consisted of gross, painless hematuria in 79% of patients, lower urinary tract symptoms in 16%, and microhematuria in 5%.
  • The primary treatment modalities used were surgery in 16 (84%) patients, chemotherapy in 2 (11%), and palliation in 1 (5%).
  • The rate of local and distal recurrence was 16% and 53%, respectively.
  • There was no statistically significant difference in disease-specific survival between patients with bladder leiomyosarcoma compared to other sarcoma subtypes (P = 0.149).
  • CONCLUSIONS: Bladder sarcoma is a highly aggressive malignancy, regardless of its histologic subtype.
  • [MeSH-major] Sarcoma / therapy. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17208137.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


6. Aki H, Baslar Z, Uygun N, Ozguroglu M, Tuzuner N: Primary granulocytic sarcoma of the urinary bladder: case report and review of the literature. Urology; 2002 Aug;60(2):345
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary granulocytic sarcoma of the urinary bladder: case report and review of the literature.
  • We report a case of granulocytic sarcoma of the urinary bladder, with no evidence of hematologic involvement.
  • The patient was initially misdiagnosed and was treated with chemotherapy for transitional carcinoma grade 3.
  • Despite this treatment, the clinical features of the patient progressed, and a repeated biopsy yielded the correct diagnosis.
  • Three cases of granulocytic sarcoma of the urinary bladder have been reported in published studies, with only one of these primary.
  • To our knowledge, ours is the second case of granulocytic sarcoma of the urinary bladder presenting with urologic symptoms but without hematologic findings.
  • [MeSH-major] Sarcoma, Myeloid. Urinary Bladder Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Humans. Idarubicin / administration & dosage. Male. Methotrexate / administration & dosage. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12137850.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin; M-VAC protocol
  • [Number-of-references] 8
  •  go-up   go-down


7. El-Sherbiny MT, El-Mekresh MH, El-Baz MA, Ghoneim MA: Paediatric lower urinary tract rhabdomyosarcoma: a single-centre experience of 30 patients. BJU Int; 2000 Aug;86(3):260-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric lower urinary tract rhabdomyosarcoma: a single-centre experience of 30 patients.
  • OBJECTIVE: To retrospectively analyse the long-term outcome of children with bladder and/or prostate rhabdomyosarcoma who were diagnosed at the authors' institution over the last 17 years.
  • The initial biopsy showed an embryonal variant in 27 and round-cell sarcoma in three patients.
  • Subsequent treatment depended upon the response to chemotherapy.
  • RESULTS: Fourteen patients had a complete or partial response to chemotherapy (> 50% reduction in tumour size); they were maintained on VAC chemotherapy for 2 years.
  • Additional therapies were used in three patients, i.e. radical cystectomy in one and external irradiation in two.
  • Sixteen patients had a minimal response to chemotherapy; in six, radical cystectomy was feasible and was followed by one year of chemotherapy.
  • CONCLUSION: The tumour response to initial chemotherapy can be used to stratify patients into two risk-groups, i.e. low-risk patients with a complete or partial response in whom the bladder could be salvaged, and high-risk patients with a minimal response, in whom intensive treatment should be pursued, with no attempt at bladder salvage.
  • [MeSH-major] Prostatic Neoplasms / therapy. Rhabdomyosarcoma / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10930927.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


8. Rassnick KM, Frimberger AE, Wood CA, Williams LE, Cotter SM, Moore AS: Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med; 2000 May-Jun;14(3):271-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of ifosfamide for treatment of various canine neoplasms.
  • Complete responses were seen in 1 dog with metastatic leiomyosarcoma of the urinary bladder and in 1 dog with metastatic cutaneous hemangiosarcoma.
  • Six dogs with splenic hemangiosarcoma received ifosfamide postsplenectomy and their median survival time was 147 days.
  • No dog developed clinical or microscopic evidence of hemorrhagic cystitis.
  • Ifosfamide appears safe to use in tumor-bearing dogs, and the evaluation of combination chemotherapy protocols that include ifosfamide should be considered.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10830540.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Cruz Guerra NA, Linares Quevedo A, Cuesta Roca C, Jiménez Cidre M: [Low-grade sarcoma of the endometrial stroma: late recurrence with ureteral and bladder involvement]. Arch Esp Urol; 2002 Oct;55(8):946-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low-grade sarcoma of the endometrial stroma: late recurrence with ureteral and bladder involvement].
  • [Transliterated title] Sarcoma de bajo grado del estroma endometrial: recidiva tardía con afectación ureteral y vesical.
  • OBJECTIVE: To report a new case of low grade endometrial stroma sarcoma late relapse involving bladder wall and ureter.
  • Image diagnostic tests--mainly CT-scan--evidenced a right pelvic mass involving the bladder wall and the homolateral distal ureter.
  • Different lines of palliative treatment--chemotherapy and radiotherapy--were started.
  • RESULTS: Histologic and immunohistochemical studies of samples obtained by transvaginal ultrasound guided biopsies were consistent with low grade endometrial stroma sarcoma.
  • Results from palliative treatment were discouraging.
  • CONCLUSIONS: This type of neoplasms are rare, although relapses may appear after extremely long silent periods.
  • Although there are publications reporting good results, the role of different palliative therapeutic alternatives is not well established yet, and responses in cases like ours are minimal or none.
  • [MeSH-major] Endometrial Neoplasms / pathology. Sarcoma, Endometrial Stromal / secondary. Ureteral Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Hematuria / etiology. Humans. Hydronephrosis / complications. Hysterectomy. Megestrol / administration & dosage. Middle Aged. Palliative Care. Radioisotope Teletherapy. Radiotherapy, Adjuvant. Thrombophilia / complications. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MEGESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12455286.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EA6LD1M70M / Megestrol
  •  go-up   go-down


10. Queipo Zaragozá JA, Chicote Pérez F, Borrell Palanca A, Beltrán Meseguer JF, Alcalá-Santaella Casanova C, Martínez García B, Pastor Sempere F: [Unusual bladder tumors: primary epidermoid carcinoma, adenocarcinoma, and sarcoma. Clinical behavior. Our experience]. Actas Urol Esp; 2003 Feb;27(2):123-31
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual bladder tumors: primary epidermoid carcinoma, adenocarcinoma, and sarcoma. Clinical behavior. Our experience].
  • [Transliterated title] Tumores vesicales inusuales: carcinoma epidermoide, adenocarcinoma y sarcoma primarios. Comportamiento clínico. Nuestra experiencia.
  • INTRODUCTION AND OBJECTIVES: Non-transitional cell tumours of the bladder are both a diagnostic challenge for the pathologist and a therapeutic challenge for the urologist, because although uncommon (less than 5% of all malignancies of the bladder) they show different biological behaviours each requiring a unique approach.
  • The most significant pathoanatomical types are: primary epidermoid carcinoma, primary adenocarcinoma and primary sarcoma.
  • This paper presents an analysis of our experience in these types of tumours.
  • MATERIAL AND METHODS: A retrospective study of unusual cases of cancer of the bladder seen in our hospital between 1988-2001.
  • Their biological behaviour and the therapies applied are analysed.
  • RESULTS: We found 21 cases of the following pathoanatomical varieties: 13 epidermoid carcinomas, 7 adenocarcinomas (3 urachal) and 1 sarcoma.
  • At the time of diagnosis 19 patients had locally advanced stages (> or = T2).
  • Although elective therapy was cystectomy, this was only feasible in 10 cases.
  • Systemic chemotherapy (most frequently M-VAC) and/or local radiotherapy was used in 7 cases.
  • CONCLUSIONS: Late diagnosis of these tumours and their aggressive biological behaviour involve a gloomy prognosis.
  • Only early diagnosis and radical therapy could improve the prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Sarcoma / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Female. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Spain / epidemiology. Survival Analysis

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12731327.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 37
  •  go-up   go-down


11. Kazanowska B, Mikołajewska A, Balcerska A, Balwierz W, Bodalski J, Dłuzniewska A, Drozyńska E, Kurylak A, Reich A, Stencel D, Szewczyk B, Wachowiak J, Wysocki M, Chybicka A: [Soft tissue sarcoma of the bladder and prostate. A report of the Polish Paediatric Solid Tumour Group (PPSTG)]. Med Wieku Rozwoj; 2004 Oct-Dec;8(4 Pt 2):1091-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcoma of the bladder and prostate. A report of the Polish Paediatric Solid Tumour Group (PPSTG)].
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children younger then 15 years of age.
  • The treatment of RMS localized in bladder or prostate still remains controversial.
  • The aim of this study was analysis of treatment results in children with soft tissue sarcoma of bladder and prostate.
  • From 1993 to 2001 the PPSTG has used three protocols to treat soft tissue sarcomas in children.
  • After biopsy confirmation of the diagnosis patients were treated with chemotherapy and subsequent surgery.
  • The median follow-up time was 42 months.
  • RMS-embryonal was diagnosed in 11 patients, RMS-alveolare in 4 and others types in 4.
  • Sixteen patients presented clinical stage III and 3 stage IV The tumours were primarily localised in bladder in 16 patients and prostate in 3.
  • After induction chemotherapy two patients received partial cystectomy, 5 complete cystectomy and 3 complete cystectomy with genitourinary reconstructive.
  • The most common treatment failure was isolated, local relapse in 8 children particularly in patients with any second surgery.
  • Significant prognostic factors are the initial tumours volume, the lymph nodes infiltration and the response to the first chemotherapy cycle.
  • Surgery is the most important procedure in local control of soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms. Rhabdomyosarcoma. Urinary Bladder Neoplasms
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Cystectomy / methods. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Poland. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951604.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Spiess PE, Tuziak T, Tibbs RF, Bassett R, Tamboli P, Brown GA, Grossman HB, Ayala AG, Czerniak B: Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol; 2007 May;38(5):753-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudosarcomatous and sarcomatous proliferations of the bladder.
  • Pseudosarcomatous fibromyxoid tumor (PFT), postoperative spindle cell nodule (PSN), sarcoma, and sarcomatoid carcinoma of the bladder are frequently difficult to distinguish histopathologically with significant differences in disease-related outcomes.
  • A retrospective review of our pathology registry over the last 25 years identified 7 PFT, 10 PSN, 18 primary bladder sarcomas, and 17 sarcomatoid carcinomas.
  • Most patients with PFT, PSN, sarcoma, and sarcomatoid carcinoma were diagnosed between the ages of 50 to 60 years with PFT and PSN most commonly detected in women.
  • A previous history of urological instrumentation and bladder cancer was present in all patients with PSN but none of the patients with PFT.
  • Pseudosarcomatous fibromyxoid tumors were characterized by a tissue culture-like proliferation of myofibroblastic cells with focal atypia and overall cytoarchitectural features mimicking nodular fasciitis.
  • In contrast, local recurrences and distant metastases frequently occurred in patients with primary sarcoma and sarcomatoid carcinoma despite aggressive surgical management, which was often combined with neoadjuvant chemotherapy (50% and 65% disease-specific mortality, respectively).
  • Pseudosarcomatous fibromyxoid tumor and PSN have unique clinical and pathologic features that allow their distinction from primary bladder sarcoma and sarcomatoid carcinoma.
  • [MeSH-major] Sarcoma / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306332.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Osone S, Hosoi H, Tanaka K, Tsuchiya K, Iehara T, Morimoto A, Hashida T, Yamashita M, Kawabata K, Nishijo K, Toguchida J, Hata J, Sugimoto T: A case of a ewing sarcoma family tumor in the urinary bladder after treatment for acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2007 Dec;29(12):841-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a ewing sarcoma family tumor in the urinary bladder after treatment for acute lymphoblastic leukemia.
  • We report the first case of a tumor of the Ewing sarcoma family of tumors arising from the urinary bladder 3 years after chemotherapy for acute lymphoblastic leukemia.
  • Ultrasonography and computed tomography revealed a 1-cm sized intravesical tumor.
  • EWS-FLI1 fusion transcripts were detected in the tumor tissue by reverse transcriptase polymerase chain reaction.
  • These findings support the diagnosis of Ewing sarcoma family of tumor.
  • After adjuvant multidrug chemotherapy, the patient has shown no evidence of disease for more than 2 years.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sarcoma, Ewing / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090934.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Gupta NP, Ansari MS, Khaitan A, Dawar R: Fertility preserving radical cystectomy in a young female with malignant mesenchymal tumour of urinary bladder. Int Urol Nephrol; 2003;35(4):501-2
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility preserving radical cystectomy in a young female with malignant mesenchymal tumour of urinary bladder.
  • We present a case of 19-year-old lady with mesenchymal tumour of urinary bladder with myogenic differentiation who was managed with fertility preserving radical cystectomy.
  • Adjuvant chemotherapy (Ifosfamide, CDDP and Etocid) was given.
  • [MeSH-major] Cystectomy / methods. Fertility. Sarcoma / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Female. Humans. Mesenchymal Stromal Cells / pathology. Treatment Outcome. Urinary Diversion. Urologic Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1999 Jun;161(6):1761-4 [10332430.001]
  • [Cites] J Urol. 2001 Jan;165(1):51-5; discussion 55 [11125362.001]
  • [Cites] Int J Gynecol Cancer. 1999 Jul;9(4):302-306 [11240783.001]
  • (PMID = 15198154.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Gruessner SE, Omwandho CO, Dreyer T, Blütters-Sawatzki R, Reiter A, Tinneberg HR, Bohle RM: Management of stage I cervical sarcoma botryoides in childhood and adolescence. Eur J Pediatr; 2004 Aug;163(8):452-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of stage I cervical sarcoma botryoides in childhood and adolescence.
  • Rhabdomyosarcomas are the most common soft tissue sarcomas in childhood.
  • The botryoid variant arises in infancy from the vagina or urinary bladder and extremely rarely from the uterine cervix.
  • Treatment regimes range from local excision of the tumour to radical hysterectomy with adjuvant multidrug therapy and/or radiotherapy.
  • In cases of minimal cervical invasion, the less invasive local excision in combination with adjuvant chemotherapy has resulted in excellent survival rates with complete functional preservation of the bladder, rectum, vagina, and ovaries.
  • We present here a 30-year literature review and a case report of a cervical sarcoma botryoides in a 5-year-old girl.
  • CONCLUSION: based on the literature review and our own observation, we recommend minor surgical approaches in combination with chemotherapy as the treatment of choice for early stage I cervical rhabdomyosarcoma.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / pathology. Rhabdomyosarcoma, Embryonal / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Child, Preschool. Dactinomycin / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Neoplasm Staging. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Sarcoma botryoides.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Springer-Verlag
  • [Cites] Eur J Cancer. 2001 Apr;37(6):767-74 [11311652.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):747-60, xii [10836015.001]
  • [Cites] Obstet Gynecol. 1975 Feb;45(2):175-80 [1090863.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1552-60 [3621128.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jun;176(6):1563-9 [11373233.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2003 Feb;17(1):149-68 [12758232.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):112-20 [12806368.001]
  • [Cites] Cancer. 1975 Mar;35(3):677-86 [1111936.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(5):499-500 [11198042.001]
  • [Cites] J Pediatr Surg. 1985 Dec;20(6):718-24 [3910785.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Cancer. 2003 May 15;97(10):2597-604 [12733159.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(5):335-7 [8933824.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):102-6 [9345364.001]
  • [Cites] J Surg Oncol. 2001 May;77(1):65-71 [11344486.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):1-6 [12764734.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2427-34 [10856103.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jun;25(6):448-52 [12794522.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1050-62 [9849454.001]
  • [Cites] Ann N Y Acad Sci. 1967 May 10;142(3):694-708 [5231254.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Am J Surg. 2002 Dec;184(6):484-91 [12488143.001]
  • [Cites] Med Pediatr Oncol. 2001 Apr;36(4):481-8 [11260572.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):119-24 [2403958.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Pediatr Surg. 1999 May;34(5):731-4; discussion 734-5 [10359173.001]
  • [Cites] Obstet Gynecol. 1985 Aug;66(2):262-6 [3839576.001]
  • [Cites] Arch Dis Child. 2003 Apr;88(4):354-7 [12651771.001]
  • [Cites] Cancer. 1973 Dec;32(6):1310-6 [4202189.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2117-22 [10561266.001]
  • (PMID = 15173941.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 32
  •  go-up   go-down


16. Kim JY, Cho YM, Ro JY: Prostatic stromal sarcoma with rhabdoid features. Ann Diagn Pathol; 2010 Dec;14(6):453-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic stromal sarcoma with rhabdoid features.
  • Computed tomography of the abdomen revealed an ovoid mass in the prostate invading rectum and urinary bladder.
  • A needle biopsy was diagnosed as an unclassified spindle cell sarcoma, and 2 cycles of adriamycin-based neoadjuvant chemotherapy were given, followed by radical prostatectomy.
  • The prostatectomy specimen revealed a high-grade sarcoma with fascicles of highly cellular spindle cells and numerous mitoses with hemorrhage and necrosis.
  • The tumor recurred in the bladder, and the patient died of sepsis.
  • The tumor showed an aggressive clinical behavior with a short-term survival (7 months after diagnosis).
  • [MeSH-major] Prostatic Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074696.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


17. Black PC, Brown GA, Dinney CP: The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol; 2009 Jan-Feb;27(1):3-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of variant histology on the outcome of bladder cancer treated with curative intent.
  • Patient risk stratification is essential for optimal management of patients with bladder cancer.
  • Risk status determines the application and timing of therapeutic interventions such as repeat transurethral resection, intravesical chemo- and immunotherapy, systemic chemotherapy, and radical cystectomy.
  • One key factor in such risk stratification appears to be the presence of variant histologic patterns in the bladder tumor.
  • In this review, we focus on the implications of aberrant differentiation on the management of patients with bladder cancer.
  • Although radical cystectomy remains the mainstay of treatment in all forms of bladder cancer, we highlight the use of neoadjuvant chemotherapy in patients with subtypes responsive to such therapy.
  • [MeSH-major] Medical Oncology / methods. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Algorithms. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Cell Differentiation. Humans. Prognosis. Risk. Sarcoma / pathology. Sarcoma / therapy. Treatment Outcome. Urothelium / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367107.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA91846; United States / PHS HHS / / T32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


18. Cheng L, Foster SR, MacLennan GT, Lopez-Beltran A, Zhang S, Montironi R: Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum? J Urol; 2008 Oct;180(4):1235-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Inflammatory myofibroblastic tumor of the genitourinary tract is a spindled soft tissue lesion that is often mistaken for sarcoma.
  • Aggressive therapy (radical cystectomy, radiation or chemotherapy) is unwarranted given the indolent and often benign clinical course for the majority of cases.
  • To understand the diagnostic and prognostic implications future emphasis should be placed on the link between genetic abnormalities, and clinical course, therapeutic response and ultimate outcome.
  • [MeSH-major] Carcinoma / pathology. Granuloma, Plasma Cell / pathology. Sarcoma / pathology. Urogenital Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Incidence. Neoplasm Staging. Prognosis. Risk Assessment. Ureteral Neoplasms / diagnosis. Ureteral Neoplasms / pathology. Urethral Neoplasms / diagnosis. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707729.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


19. Amsellem-Ouazana D, Cornud F, Conquy S, Beuzeboc P, Massault PP, Vieillefond A, Flam T, Zerbib M, Debré B: Management of a malignant urinary fistula by ureteral embolization with coils. Urology; 2006 Aug;68(2):427.e1-3
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of a malignant urinary fistula by ureteral embolization with coils.
  • We report the case of a 42-year-old man with a synovial sarcoma of the prostate, metastatic at presentation, who after aggressive chemotherapy followed by extensive surgery developed a complex pelvic fistula involving the lower ureter, bladder, and enteral structures.
  • Complete ureteral occlusion was obtained with a minimally invasive procedure and allowed total symptomatic relief.
  • [MeSH-major] Embolization, Therapeutic / instrumentation. Intestinal Fistula / therapy. Prostatic Neoplasms / complications. Sarcoma / complications. Urinary Fistula / etiology. Urinary Fistula / therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904469.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Armah HB, Parwani AV: Sarcomatoid urothelial carcinoma with choriocarcinomatous features: first report of an unusual case. Urology; 2007 Oct;70(4):812.e11-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old man presented with gross hematuria and a polypoid right lateral bladder mass.
  • Treatments included surgery, chemotherapy, and radiation therapy.
  • This is the first report, to our knowledge, indicating both sarcomatoid and choriocarcinomatous features in a conventional urothelial carcinoma of the bladder.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Choriocarcinoma / pathology. Sarcoma / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991575.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Cecchetto G, Carretto E, Bisogno G, Dall'Igna P, Ferrari A, Scarzello G, Donfrancesco A, Alaggio R, Indolfi P, Carli M: Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer; 2008 Nov;51(5):593-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
  • PROCEDURE: We analyzed data from 39 patients (age: 0.5-194 months, median 52) who were enrolled between 1988 and 2005 in 2 consecutive Italian Studies, RMS 88 and RMS 96.
  • All achieved a complete resection of the residual tumor after neoadjuvant chemotherapy; 27 did not receive any other local treatment: pelvic 8, extremities 6, head-neck-non-parameningeal 5, orbit 1, genito-urinary-bladder-prostate 3, trunk 2, abdomen 1, vagina 1; 12 were given RT (32-45 Gy), 5 before and 7 after the operation: genito-urinary-bladder-prostate 3, pelvic 3, abdominal 1, extremities 1, head-neck-parameningeal 1, head-neck-non-parameningeal 1, vagina 1, orbit 1.
  • All received postoperative chemotherapy.
  • The two relapses after RT occurred in huge bladder-prostate RMS.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Sarcoma

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18668515.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Kumar N, Hegarty PK, Johal N, Ismail M, Mushtaq I: Transpubic radical prostatectomy: a novel approach for rhabdomyosarcoma of the prostate in children. Pediatr Surg Int; 2006 May;22(5):453-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma is the most common soft tissue sarcoma, representing 10-15% of all malignant solid tumours in children and can occur in any site.
  • The management involves a combination of chemotherapy, radiotherapy and surgery.
  • [MeSH-minor] Anastomosis, Surgical. Child. Humans. Male. Suture Techniques. Urethra / surgery. Urinary Bladder / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Surg Int. 2004 Jun;20(6):449-54 [15095103.001]
  • [Cites] J Urol. 1973 May;109(5):866-7 [4699686.001]
  • [Cites] J Urol. 1984 Dec;132(6):1131-3 [6502802.001]
  • [Cites] Br J Urol. 1984 Dec;56(6):694-7 [6534493.001]
  • [Cites] J Urol. 1977 Feb;117(2):202-5 [833969.001]
  • [Cites] Eur Urol. 1976;2(6):300-2 [1027563.001]
  • [Cites] BJU Int. 2004 Jan;93(1):125-9 [14678383.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Pediatr Surg. 1989 Oct;24(10):977-81 [2809970.001]
  • (PMID = 16598509.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Mitsuhashi T, Nakayama M, Sakurai S, Fujimura M, Shimizu Y, Ban S, Ogawa F, Hirose T, Ishihara O, Shimizu M: KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. Ann Diagn Pathol; 2007 Feb;11(1):49-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
  • Undifferentiated endometrial sarcoma (UES) is a high-grade sarcoma that lacks specific differentiation.
  • The mass in the hysterectomy specimen consisted of pleomorphic cells that did not show any endometrial stromal or smooth muscle differentiations; thus, the diagnosis of UES was made.
  • Multiple regional recurrences around the urinary bladder were noted after 5 months, and treatment with imatinib mesylate was started, based on the provisional interpretation of KIT immunoreactivity on a biopsy specimen of the recurrent tumor.
  • Two weeks later, the tumor shrunk significantly, as evaluated by computed tomography.
  • However, they became enlarged under the therapy after 3 months since imatinib was first started.
  • The amplified EGFR in UES has not been reported previously, and further studies are necessary to consider the possibility of EGFR-targeted therapy in such sarcomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Receptor, Epidermal Growth Factor / genetics. Sarcoma / drug therapy. Sarcoma / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240308.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / DNA, Neoplasm; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


24. Cheon J, Moon DG, Cho HY, Park HS, Kim JJ, Gardner TA, Kao C: Adenovirus-mediated suicide-gene therapy in an orthotopic murine bladder tumor model. Int J Urol; 2002 May;9(5):261-7
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenovirus-mediated suicide-gene therapy in an orthotopic murine bladder tumor model.
  • BACKGROUND: Patients with high-grade transitional-cell carcinoma (TCC) of the bladder frequently experience recurrence and progress and have a low response rate to chemotherapy in metastatic TCC.
  • In this study, we evaluated the feasibility and long-term efficacy of suicide-gene therapy using adenovirus (Ad)-mediated herpes simplex virus thymidine kinase gene (HSV-TK) and prodrug ganciclovir (GCV) as a potential therapeutic approach in murine-orthotopic models of TCC.
  • METHODS: A replication defective adenoviral vectors containing toxic HSV-TK gene under the transcriptional control of RSV (Rous sarcoma virus) promoter (Ad-RSV-TK) was used.
  • Orthotopic bladder TCC was established with 1 x 106 murine (MBT-2) TCC cells in syngenic C3H/He female mice.
  • Intratumoral injection of Ad-RSV-TK in combination with GCV (20 mg/kg body weight/day i.p. b.i.d. x 7 days) was administered in vivo for the determination of treatment efficacy and long-term host survival in separate controlled experiments.
  • RESULTS: In vivo experiments demonstrated greater than three-fold reductions in MBT-2 tumor growth for the animals treated with Ad-RSV-TK (5 x 108 plaque forming units (pfu)/GCV therapy (P < 0.01)).
  • CONCLUSIONS: Suicide-gene therapy using Ad-RSV-TK/GCV provides an effective therapy in an experimental murine orthotopic bladder cancer by significantly inhibiting tumor growth and improving long-term host survival.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Genetic Therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adenoviridae / genetics. Animals. Antiviral Agents / therapeutic use. Disease Models, Animal. Female. Ganciclovir / therapeutic use. Mice. Mice, Inbred C3H. Simplexvirus. Thymidine Kinase / genetics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060439.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


25. Filov VA, Reztsova VV, Kil'maeva NE, Petukhov DV, Pinchuk BT: [An experimental study of the antitumor properties of olipifat]. Vopr Onkol; 2000;46(3):332-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Olipiphat is an original lignin-based mix developed by special technology.
  • It showed antitumor action against carcinoma of Ehrlich, breast adenocarcinoma Ca 755, melanoma B 16, lung carcinoma of Lewis, lymphosarcoma of Pliss, Walker's carcinoma, sarcoma 45 (tumor growth inhibition by 83-92%, increase in survival by 42-54%) and spontaneous murine tumors (the total of 9 pathologies).
  • The drug was administered by 3-5 injections at 2-3 day intervals.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lignin / analogs & derivatives. Lignin / therapeutic use. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Benzopyrenes. Carcinoma, Squamous Cell. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Humans. Mice. Mice, Inbred Strains. Mouth Neoplasms. Neoplasm Transplantation. Rats. Time Factors. Tumor Cells, Cultured / drug effects. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976281.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] RUSSIA
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzopyrenes; 0 / olipifat; 9005-53-2 / Lignin
  •  go-up   go-down


26. Moog R, Burger AM, Brandl M, Schüler J, Schubert R, Unger C, Fiebig HH, Massing U: Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother Pharmacol; 2002 May;49(5):356-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vivo efficacies of GemLip and GemConv were compared using the subcutaneously growing human soft tissue sarcoma SXF 1301 and the orthotopically growing human bladder cancer BXF 1299T.
  • PK and biodistribution were evaluated using radiolabeled drug and lipid in SXF 1301 tumor-bearing nude mice.
  • Furthermore, GemLip was active in the orthotopically growing BXF 1299T bladder cancer model at 6 mg/kg and prevented distant organ metastasis.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Antimetabolites, Antineoplastic / pharmacology. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacokinetics. Deoxycytidine / pharmacology. Paclitaxel / analogs & derivatives. Sarcoma / drug therapy. Taxoids. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / pharmacokinetics. Antineoplastic Agents, Phytogenic / pharmacology. Gels. Half-Life. Humans. Liposomes. Mice. Mice, Nude. Neoplasm Transplantation. Phospholipids. Tissue Distribution. Transplantation, Heterologous. Vindesine / administration & dosage. Vindesine / pharmacokinetics. Vindesine / pharmacology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11976829.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Gels; 0 / Liposomes; 0 / Phospholipids; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; RSA8KO39WH / Vindesine
  •  go-up   go-down


27. Hoff M, Rødevand E: Development of multiple malignancies after immunosuppression in a patient with Wegener's granulomatosis. Rheumatol Int; 2005 Apr;25(3):238-40
MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This resulted in delayed diagnosis.
  • Despite incorrect diagnoses, he received appropriate immunosuppressive therapy.
  • After 2 years of therapy, he developed a spinocellular carcinoma, after 12 years a basal cell carcinoma and after 19 years both a Kaposi sarcoma and a urinary bladder carcinoma.
  • This patient illustrates a difficult therapeutic balance between prolonged treatment and the hazards of therapy.
  • [MeSH-major] Granulomatosis with Polyangiitis / drug therapy. Immunosuppressive Agents / adverse effects. Neoplasms, Multiple Primary / chemically induced. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / pathology. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Fatal Outcome. Humans. Male. Middle Aged. Risk Assessment

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jun;127(6):709-13 [11405874.001]
  • [Cites] Chest Surg Clin N Am. 1999 Feb;9(1):63-77, viii [10079980.001]
  • [Cites] Arthritis Rheum. 2000 May;43(5):1021-32 [10817555.001]
  • [Cites] J Am Soc Nephrol. 1998 May;9(5):842-52 [9596082.001]
  • [Cites] Ann Intern Med. 1996 Mar 1;124(5):477-84 [8602705.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177-86 [10025742.001]
  • [Cites] Arthritis Rheum. 1988 Apr;31(4):465-70 [3358809.001]
  • [Cites] Biochem Pharmacol. 1979 Jul 1;28(13):2045-9 [475846.001]
  • [Cites] Curr Opin Rheumatol. 2002 Jan;14(1):15-22 [11790991.001]
  • [Cites] Arch Intern Med. 1988 May;148(5):1201-3 [3365087.001]
  • [Cites] Drugs. 1991 Nov;42(5):781-95 [1723374.001]
  • [Cites] Cancer. 1964 Oct;17:1348-55 [14236768.001]
  • [Cites] J Rheumatol. 2003 Mar;30(3):622-4 [12610826.001]
  • [Cites] Ann Intern Med. 1992 Mar 15;116(6):488-98 [1739240.001]
  • (PMID = 15660233.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


28. Mikhina ZP, Tkachëv SI, Trofimova OP, Ivanov SM, Medvedev SV, Zakharov SN, Krat VB, Korgunov SV: [Effectiveness of treatment of single cerebral metastasis depending on prognostic groups (RPA RTOG)]. Vopr Onkol; 2009;55(2):205-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effectiveness of treatment of single cerebral metastasis depending on prognostic groups (RPA RTOG)].
  • Single dosage of 2-2.5 Gy was administered to 158 (57.9%), 115--3Gy and more (42.1%).
  • Mean total dosage was 36 Gy per metastasis for the whole brain and 46 Gy--for total plus local exposure.
  • The following four treatment modalities were used:.
  • 2) chemotherapy > or = radiotherapy --> chemotherapy successively (56);.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Cranial Irradiation
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Head and Neck Neoplasms / pathology. Humans. Karnofsky Performance Status. Kidney Neoplasms / pathology. Lymphoproliferative Disorders / complications. Male. Middle Aged. Neoplasms, Unknown Primary / pathology. Predictive Value of Tests. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Sarcoma / secondary. Testicular Neoplasms / pathology. Urinary Bladder Neoplasms / pathology. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514377.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


29. Hu F, Hu XH, Yu P, Zhang JX, Lou GG, Liu HL, Wu B, Zhao RH, Xia HQ, Wang Y, Chen J, Ben Y, Chen SY: [Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating]. Ai Zheng; 2006 Aug;25(8):919-24
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: The abscopal effect on the tumors is a distant antitumor activity induced by local treatments.
  • METHODS: Five patients with histologically confirmed, surgically unresectable metastatic malignant tumors (2 nasopharyngeal carcinomas, 1 pulmonary carcinoma, 1 parosteal sarcoma and 1 bladder carcinoma) that had definitely failed to the conventional chemotherapy and radiotherapy or refused these therapies were enrolled in this experimental therapy.
  • Three patients responded to the novel therapy variously and eventually died from the disease, who survived 29, 15 and 13 months, respectively.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Oncolytic Virotherapy. Oncolytic Viruses / physiology
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adenoviridae / genetics. Adenoviridae / physiology. Aged. Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / therapy. Female. Follow-Up Studies. Humans. Injections, Intralesional. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / therapy. Treatment Outcome. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965669.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


30. Kato K, Arai K, Tanaka Y, Ijiri R, Kato Y, Kigasawa H, Toyoda Y, Aida N, Ohama Y: Epithelioid leiomyosarcoma in a non-immunocompromised infant: additional differential diagnosis of pediatric "round cell tumors". Mod Pathol; 2000 Oct;13(10):1156-60
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid leiomyosarcoma in a non-immunocompromised infant: additional differential diagnosis of pediatric "round cell tumors".
  • The age, clinical presentation, and histologic findings mostly favored Ewing's sarcoma/primitive neuroectodermal tumor.
  • Silver stain, however, demonstrated well-developed reticulin fibers often outlining individual tumor cells.
  • The diagnosis of epithelioid leiomyosarcoma was made.
  • Following reduction in tumor size by chemotherapy, the serum NSE level was normalized.
  • From the surgical finding, the primary site was presumed to be the urachus or the urinary bladder dome.
  • [MeSH-major] Abdominal Neoplasms / pathology. Immunocompromised Host. Leiomyosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11048812.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


31. Hensley ML, Dizon D, Derosa F, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Colevas AD, Spriggs D, Aghajanian C: A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs; 2007 Aug;25(4):335-41
Hazardous Substances Data Bank. Ixabepilone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dose-limiting toxicity definitions were based on severe myelosuppression, or grade 3 or 4 treatment-related non-hematologic toxicity, or dose delay of greater than 2 weeks due to treatment toxicity observed in the first treatment cycle.
  • Treatment-related toxicities included neutropenia, thrombocytopenia, neutropenic fever, hypophosphatemia, and hyponatremia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carcinoma, Small Cell / drug therapy. Cohort Studies. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Epothilones / administration & dosage. Female. Humans. Kidney Neoplasms / drug therapy. Leukopenia / chemically induced. Lung Neoplasms / drug therapy. Male. Melanoma / drug therapy. Middle Aged. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Urinary Bladder Neoplasms / drug therapy. Uterine Neoplasms / drug therapy. Water-Electrolyte Imbalance / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8724-9 [16314632.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1439-46 [15735119.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(2):169-70 [12701971.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1082-8 [17261851.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):314-9 [14751176.001]
  • [Cites] J Antibiot (Tokyo). 1996 Jun;49(6):560-3 [8698639.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15 [8893876.001]
  • [Cites] Anticancer Drugs. 2004 Jul;15(6):553-8 [15205596.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2325-33 [7757983.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):593-6 [13678730.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2534-41 [8999970.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Invest New Drugs. 2006 Nov;24(6):515-20 [16699973.001]
  • (PMID = 17364235.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01-CA69856
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epothilones; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; K27005NP0A / ixabepilone
  •  go-up   go-down


32. Pedersen AF, Zachariae R, Jensen AB, Bovbjerg DH, Andersen O, von der Maase H: Psychological stress predicts the risk of febrile episodes in cancer patients during chemotherapy. Psychother Psychosom; 2009;78(4):258-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychological stress predicts the risk of febrile episodes in cancer patients during chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Fever of Unknown Origin / psychology. Neoplasms / drug therapy. Opportunistic Infections / chemically induced. Opportunistic Infections / psychology. Stress, Psychological / complications
  • [MeSH-minor] Aged. Disease Susceptibility / psychology. Female. Hospitalization. Humans. Leukocyte Count. Lung Neoplasms / drug therapy. Lung Neoplasms / immunology. Lung Neoplasms / psychology. Male. Middle Aged. Neutrophils. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / immunology. Ovarian Neoplasms / psychology. Personality Inventory. Risk Factors. Sarcoma / drug therapy. Sarcoma / immunology. Sarcoma / psychology. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / immunology. Urinary Bladder Neoplasms / psychology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19468261.001).
  • [ISSN] 1423-0348
  • [Journal-full-title] Psychotherapy and psychosomatics
  • [ISO-abbreviation] Psychother Psychosom
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


33. Vincentelli F, Caruso G, Figarella-Branger D: Primary intradural Ewing's sarcoma of the cauda equina presenting with acute bleeding. Acta Neurochir (Wien); 2010 Mar;152(3):563-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intradural Ewing's sarcoma of the cauda equina presenting with acute bleeding.
  • [MeSH-major] Cauda Equina / pathology. Hemorrhage / pathology. Polyradiculopathy / pathology. Sarcoma, Ewing / pathology. Spinal Neoplasms / pathology. Subarachnoid Space / pathology
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Decompression, Surgical. Doxorubicin / therapeutic use. Drug Therapy / methods. Female. Humans. Ifosfamide / therapeutic use. Lumbar Vertebrae / pathology. Lumbar Vertebrae / surgery. Magnetic Resonance Imaging. Neurosurgical Procedures. Paraparesis / etiology. Paraparesis / pathology. Paraparesis / physiopathology. Radiotherapy / methods. Spinal Nerve Roots / blood supply. Spinal Nerve Roots / parasitology. Spinal Nerve Roots / surgery. Treatment Outcome. Urinary Bladder, Neurogenic / etiology. Urinary Bladder, Neurogenic / pathology. Urinary Bladder, Neurogenic / physiopathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779671.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Austria
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


34. Vaporciyan AA, Putnam JB Jr, Smythe WR: The potential role of aprotinin in the perioperative management of malignant tumors. J Am Coll Surg; 2004 Feb;198(2):266-78
Hazardous Substances Data Bank. APROTININ .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Aprotinin / therapeutic use. Neoplasms / drug therapy. Serine Proteinase Inhibitors / therapeutic use
  • [MeSH-minor] Animals. Blood Loss, Surgical / prevention & control. Disease Progression. Female. Hemostasis. Humans. Kallikreins / physiology. Kidney / drug effects. Meningeal Neoplasms / surgery. Meningioma / surgery. Mesothelioma / surgery. Neoplasm Invasiveness. Neoplasm Metastasis / prevention & control. Neovascularization, Pathologic / physiopathology. Ovarian Neoplasms / physiopathology. Pneumonectomy. Sarcoma / surgery. Urinary Bladder Neoplasms / surgery. Urokinase-Type Plasminogen Activator / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14759785.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serine Proteinase Inhibitors; 9087-70-1 / Aprotinin; EC 3.4.21.- / Kallikreins; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Number-of-references] 75
  •  go-up   go-down






Advertisement